Hologic stock holds steady as earnings outlook points to modest growth

Hologic, Inc. (US4364401012) stock is trading close to its consensus analyst price target as of August 24, 2026, reflecting a cautious view on the company’s earnings and growth prospects. Per a recent market overview dated August 24, 2026, Hologic shares trade around $76.00 on the Nasdaq, giving the company a market capitalization of $16.97 billion and implying a price-to-earnings ratio of 31.67 based on expected earnings for the current fiscal year. This places Hologic stock slightly below the average market valuation multiple of 45.42 on the same measure.

Valuation and price context

A detailed stock analysis updated on August 24, 2026 shows Hologic shares trading in a narrow intraday band between $76.00 and $76.07, indicating relatively muted short-term volatility. The same overview reports a 52-week trading range from $51.90 to $76.07, meaning the current price is sitting right at the top of that range and more than $24 above the low over the past year. With this price level and the reported earnings outlook, the company’s P/E ratio stands at 31.67 compared with a market average multiple of 45.42, suggesting that investors pay a substantial but not extreme premium for Hologic’s healthcare equipment business relative to the broader market.

Trading liquidity also appears solid. The same snapshot lists a volume figure of 102.03 million shares against an average volume of 3.29 million shares, indicating substantial turnover in recent sessions. While this elevated cumulative volume may reflect broader sector interest, the company’s own technical picture is shaped by its move from a 52-week low of $51.90 to levels just above $76.00, a gain of more than 46 percent in that period. For investors, this upward move to the top of the 52-week range underscores that much of the re-rating has already occurred ahead of the next phase of earnings growth.

Earnings profile and guidance

Hologic follows a fiscal year schedule ending on September 30, 2026, and the latest reported quarterly results were released on January 29, 2026. That reporting date, highlighted in the same stock analysis calendar, marks the most recent official earnings update in the current cycle. According to the earnings expectations compiled there, Hologic is expected to deliver full-year earnings of $4.28 per share in the current fiscal year, with forecasts pointing to an increase to $4.62 per share in the subsequent year. This implies projected earnings growth of 7.94 percent based on consensus estimates, a modest but positive trajectory for a mature healthcare equipment company.

The earnings growth outlook sits alongside a consensus price target of $79.13 for Hologic shares. Analysts’ targets cluster in a range from $76.00 at the low end to $90.00 at the high end, with the average target only a little above the current price of around $76.00. The implied potential upside of 4.1 percent from the current price to the average target suggests that the market sees limited near-term appreciation, aligning with the hold-oriented view of the stock. In practice, that means the valuation today already embeds expectations for mid-single-digit earnings growth over the coming year, leaving relatively little room for multiple expansion without a positive surprise in revenue or margins.

Analyst stance and consensus view

Analyst sentiment around Hologic is captured in the same stock analysis with a consensus rating described as Hold. The rating is based on an average score of 2.00 on a scale where higher values correspond to more positive recommendations, and the firm currently carries no strong buy or buy ratings in that summary, alongside 12 hold ratings and no sell ratings. This configuration tells an important story for investors. Analysts do not view Hologic as an underperformer that merits a sell recommendation, but they also see limited short-term catalysts that would justify a broad upgrade cycle toward buy ratings at present valuation levels.

In practical terms, a consensus rating of Hold combined with a price target of $79.13 very close to the prevailing price of roughly $76.00 points to expectations for modest returns driven primarily by mid-single-digit earnings growth rather than by large-scale revaluation. The reported P/E ratio of 31.67 relative to the market average of 45.42 signals that the stock trades at a discount to faster-growing or more speculative segments of the market, yet still demands a premium compared with many cyclical sectors. For long-term holders, this structure highlights that execution on earnings guidance and stability in cash flows matter more than dramatic multiple expansion.

Hologic’s diagnostic and imaging franchise

Beyond the headline valuation metrics, Hologic’s core business centers on diagnostic and medical imaging solutions, particularly in women’s health. The company develops and commercializes systems for breast cancer screening, gynecological diagnostics, and molecular testing. These offerings support hospitals, diagnostic centers, and clinics with equipment and consumables that are typically embedded in routine healthcare pathways. That business profile tends to produce recurring revenue streams driven by installed equipment bases and follow-on tests, which can underpin stable earnings growth when supported by investment in new technology and regulatory approvals.

In the latest stock overview, Hologic is classified within the healthcare equipment and supplies industry, and its products compete with other diagnostic and imaging firms for capital budgets in hospitals and health systems. The company’s long-established presence, founded in 1985, and workforce of around 7,070 employees indicate a scale that enables continued research and development in areas such as digital mammography and molecular diagnostics. For investors, the combination of established installed base, recurring consumables, and innovation pipelines provides the fundamental context behind the consensus expectations for earnings rising from $4.28 per share to $4.62 per share over the next year.

Representative product: breast imaging systems

One representative segment of Hologic’s portfolio is its advanced breast imaging systems. These tools are designed to improve detection of early-stage breast cancer and to reduce recall rates in screening programs by providing higher-resolution images and better workflow integration. Installed in hospitals and dedicated imaging centers, such systems generate revenue from both equipment sales and associated service contracts. Because breast cancer screening is embedded in preventive care guidelines across many developed markets, demand for high-quality imaging systems tends to be resilient, supporting the kind of mid-single-digit earnings growth reflected in consensus forecasts.

Stock context and investor takeaway

As of August 24, 2026, Hologic stock trades on the Nasdaq exchange at around $76.00, anchored by a market capitalization of $16.97 billion and a valuation multiple of 31.67 times expected earnings. With the shares sitting at the top of their 52-week range between $51.90 and $76.07, the price level already reflects a substantial recovery from the low end of that band. Against this backdrop, the consensus analyst price target of $79.13 implies modest upside, while earnings estimates calling for a move from $4.28 to $4.62 per share highlight steady, rather than explosive, growth expectations. For investors, the key question is whether the company’s diagnostic and imaging franchise can deliver incremental growth or margin expansion beyond this baseline outlook.

Go deeper

Read more analysis on Hologic stock and its earnings outlook at the latest detailed stock overview published on August 24, 2026.

Investor Relations

More information on Hologic’s business segments, strategic initiatives, and investor updates can be found on the company’s official investor relations page at https://www.hologic.com/.

Fact box

Company: Hologic, Inc.

ISIN: US4364401012

Ticker: HOLX

Exchange: Nasdaq

Price (as of August 24, 2026): $76.00 USD

Market cap: $16.97 billion (as of August 24, 2026)

Sector / Industry: Healthcare equipment and supplies

Index membership: Nasdaq indexes including broader market benchmarks